A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Clinical Trial ID NCT01460134

PubWeight™ 13.53^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01460134

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combination cancer immunotherapy and new immunomodulatory targets.	Nat Rev Drug Discov	2015	2.25
2	Immunotherapy in the treatment of non-small cell lung cancer.	Lung Cancer	2014	1.35
3	Agonist antibodies to TNFR molecules that costimulate T and NK cells.	Clin Cancer Res	2013	1.33
4	Immune checkpoint inhibitors in clinical trials.	Chin J Cancer	2014	0.98
5	Novel antibodies targeting immune regulatory checkpoints for cancer therapy.	Br J Clin Pharmacol	2013	0.94
6	New strategies in immunotherapy for non-small cell lung cancer.	Transl Lung Cancer Res	2015	0.89
7	Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.	Front Immunol	2015	0.85
8	Principles of antibody-mediated TNF receptor activation.	Cell Death Differ	2015	0.84
9	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.	Immunotherapy	2015	0.81
10	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.	Onco Targets Ther	2016	0.81
11	The emerging role of immunotherapy in colorectal cancer.	Ann Transl Med	2016	0.80
12	Antibody-based immunotherapy for malignant glioma.	Semin Oncol	2014	0.80
13	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.	Oncotarget	2015	0.79
14	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.	J Immunol Res	2015	0.78
15	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.	J Clin Oncol	2017	0.76